Interviews

At the 2015 VEITH Symposium, Vascular Disease Management spoke with Lowell Kabnick, MD, and Jose Almeida, MD, co-chairs of the venous programming at the meeting. They describe the pros and cons related to the ways that clinicians from...

At the 2015 VIVA meeting, data were presented from a study investigating economic impact of various endovascular interventions compared to the Supera stent from Abbott Vascular. Vascular Disease Management spoke with Brian G. DeRubertis, MD,...

Craig Walker, MD, clinical professor of medicine at Tulane University School of Medicine and Louisiana State University School of Medicine in New Orleans, and founder, president, and medical director of the Cardiovascular Institute of the...

At the 5th Annual Amputation Prevention Symposium, Vascular Disease Management spoke with Thomas Davis, MD, about the Endovascular Atherectomy Safety and Effectiveness (EASE) trial, an FDA-approved Investigational Device Exemption (IDE)...

At the 5th Annual Amputation Prevention Symposium, Vascular Disease Management asked Lawrence A. Garcia, MD, to share details about subset analysis and new insights from the DEFINITIVE LE trial. The DEFINITIVE LE study was conducted at 47...

The continued study of modalities for peripheral arterial disease complemented by refinements in technique for new devices foreshadows a bright future for new endovascular approaches in the treatment of PAD.

Amputation Prevention Symposium founder and course director Jihad A. Mustapha, MD, shares details about the Peripheral RegIstry of Endovascular Clinical OutcoMEs (PRIME), which he created to help track data on critical limb ischemia (CLI)...

Larry J. Diaz-Sandoval, MD, discusses a study of CO2 angiography conducted on critical limb ischemia patients with diabetes and chronic kidney disease. 

A patient presented with complaints of what seemed to be rest pain involving his right lower extremity, which was unusual given the patient’s few risk factors. Imaging revealed what appeared to be thrombus, although ultimately the patient did...

At the 2015 New Cardiovascular Horizons meeting, Vascular Disease Management spoke with VISION trial investigator Patrick Muck, MD, and Avinger founder and CEO John B. Simpson, MD, about the VISION trial and the Pantheris system.